J&J’s Top 10 List: Updates From Pharma Business Review
Executive Summary
J&J presented a far-reaching overview of its pharmaceutical portfolio and pipeline at an analyst day May 20, including plans to break into immuno-oncology, a strategy to develop a pan-genotypic HCV regimen and several filing timelines for new drugs.
You may also be interested in...
Bapineuzumab Failure Raises More Doubts About Beta Amyloid Approach In Alzheimer’s
As many observers expected, top-line results from a Phase III study show bapineuzumab doesn’t work in carriers of the ApoE4 gene, who are at highest risk for Alzheimer’s disease. An interim analysis of another Phase III study in carriers will now be “expedited,” and other studies of non-carriers will keep going, Pfizer says.
Radius Business Review Ends In Sale To Investment Funds
Gurnet Point Capital and Patient Square Capital will buy Radius Health for approximately $890m, including a contingent value right dependent on sales growth for osteoporosis drug Tymlos.
What Sanofi Early Research Chief Scientist Frank Nestle Is Most Excited About
Sanofi's Nestle talked to In Vivo about the company's early pipeline, the emerging technologies he thinks are most promising, and tapping external innovation.